10-K: Tarsus Pharmaceuticals Reports Strong XDEMVY Sales, Advances Pipeline

Tarsus Pharmaceuticals, Inc. reports significant revenue growth from its flagship product XDEMVY, while continuing to advance its pipeline for ocular rosacea and Lyme disease prophylaxis.

Summary

• Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on eye care and infectious disease prevention.
• XDEMVY (lotilaner ophthalmic solution) 0.25%, for Demodex blepharitis, received FDA approval in July 2023 and commenced commercial launch in August 2023.
• Net product sales for XDEMVY reached $451.4 million for the full year 2025, a substantial increase from $180.1 million in 2024.
• Approximately 400,000 bottles of XDEMVY were delivered to patients in 2025, up from 163,000 in 2024.
• The company reported a net loss of $66.4 million for the year ended December 31, 2025, an improvement from $115.6 million in 2024 and $135.9 million in 2023.
• XDEMVY demonstrated statistically significant and clinically meaningful improvements in Meibomian Gland Disease (MGD) in patients with Demodex mites in the Ersa and Rhea trials.
• TP-04, an investigational gel for ocular rosacea, showed positive topline results in a Phase 2a trial for papulopustular rosacea in February 2024, leading to a Phase 2 trial initiation for ocular rosacea in December 2025.
• TP-05, an investigational oral tablet for Lyme disease prophylaxis, demonstrated statistically significant tick mortality in the Phase 2a Carpo trial in February 2024.
• The FDA agreed to the proposed approach for a Phase 2 clinical trial of TP-05, expected to include several hundred subjects, with initiation planned for Q2 2026.
• Unaided awareness of Demodex blepharitis increased to approximately 25% in 2025, up from 2% at the start of the direct-to-consumer (DTC) campaign.
• The company's cash, cash equivalents, and marketable securities totaled $417.3 million as of December 31, 2025.
• Tarsus completed follow-on public offerings in March 2025 and March 2024, raising $134.8 million and $107.7 million in net proceeds, respectively.
• The company entered into a $75.0 million initial term loan under a 2024 Credit Facility with Pharmakon in April 2024, with no financial covenants.
• An Artificial Intelligence (AI) Policy was implemented in November 2025 to ensure safe, ethical, and compliant adoption of AI technologies.
• The company is on track for potential approval of a preservative-free formulation of TP-03 in Europe in 2027 and expects potential approval of TP-03 in Greater China in 2026 through its partner GrandPharma.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, driven by the exceptional commercial success and rapid growth of XDEMVY, coupled with promising advancements in its pipeline candidates and a strong liquidity position, despite ongoing net losses.

Positives

• XDEMVY net product sales grew significantly to $451.4 million in 2025, from $180.1 million in 2024, indicating strong market acceptance and commercialization success.
• Net losses decreased to $66.4 million in 2025 from $115.6 million in 2024, showing progress towards profitability.
• XDEMVY demonstrated statistically significant and clinically meaningful improvements in Meibomian Gland Disease (MGD) in patients with Demodex mites in the Ersa and Rhea trials, expanding its potential market.
• TP-04 showed positive topline results in a Phase 2a trial for papulopustular rosacea, leading to advancement into a Phase 2 trial for ocular rosacea.
• TP-05 demonstrated statistically significant tick mortality in the Phase 2a Carpo trial, supporting its potential as a Lyme disease prophylactic.
• The FDA agreed to the proposed Phase 2 clinical trial approach for TP-05, providing a clear regulatory path forward.
• Unaided awareness of Demodex blepharitis increased substantially to 25% due to successful DTC campaigns, indicating effective market education.
• The company maintains a strong cash position with $417.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Appointment of David E.I. Pyott, a renowned biopharmaceutical leader, to the Board of Directors strengthens leadership and strategic expertise.
• Successful follow-on public offerings in March 2025 and March 2024 provided significant capital for ongoing operations and development.
• The 2024 Credit Facility with Pharmakon has no financial covenants, offering operational flexibility.

Negatives

• The company continues to incur significant net operating losses, with an accumulated deficit of $426.6 million as of December 31, 2025.
• Reliance on third-party contract manufacturers and single-source suppliers for XDEMVY and product candidates introduces supply chain risks.
• Clinical drug development is lengthy, expensive, and risky, with uncertain timelines and outcomes, and earlier trial results may not predict future success.
• The company has limited experience as a commercial company generating revenue from product sales, posing risks to sustained profitability.
• The market opportunity for XDEMVY and other product candidates may be smaller than estimated, potentially affecting sales growth.
• The company is heavily dependent on the continued successful commercialization of XDEMVY, making it vulnerable to any commercialization setbacks.
• The FDA confirmed that a Phase 3 trial for TP-05 would require a disease prevention field study involving thousands of patients, indicating a long and costly development path.
• The China Out-License with GrandPharma has variable consideration related to remaining milestone payments fully constrained as of December 31, 2025, indicating uncertainty in future revenue from this source.
• The company's existing indebtedness under the 2024 Credit Facility may limit financial flexibility and operating actions due to covenants.

Risks

• Incurring significant expenses and potential losses in the future due to ongoing commercialization of XDEMVY and pipeline development.
• Difficulty in predicting capital requirements and potential need for additional funding, which if not obtained, could delay or eliminate product development and commercialization efforts.
• Unsuccessful commercialization of XDEMVY or future approved products due to limited experience as a commercial company.
• Heavy dependence on the continued successful commercialization of XDEMVY and successful development, regulatory approvals, and commercialization of current and future product candidates.
• Failure to successfully educate Eye Care Professionals (ECPs) and the market about the need for treatments specifically for Demodex blepharitis and other targeted diseases.
• Market acceptance of XDEMVY or other product candidates may be lower than estimated, or adequate formulary coverage, pricing, or reimbursement may not be achieved.
• Overestimating the size of market opportunities for products, leading to adversely affected sales growth.
• Dependence on intellectual property licensed from Elanco; breach or termination of agreements could lead to loss of license rights.
• Difficulties in managing growth as development, regulatory, operational, sales, marketing, and distribution capabilities expand.
• Reliance on third parties for commercial manufacturing and single-source suppliers for materials, increasing risk of insufficient supply or unacceptable costs.
• Clinical drug development is lengthy, expensive, and risky, with uncertain timelines and outcomes; earlier results may not be predictive.
• Termination or suspension of, or delays in, planned clinical trials could increase costs and delay revenue generation.
• Reliance on third parties to conduct clinical trials and research; unsatisfactory performance or missed deadlines could delay development programs.
• Inability to obtain and maintain sufficient intellectual property protection for products, allowing competitors to commercialize similar products.
• Inadequate patent terms to protect competitive position for product candidates and preclinical programs.
• Information technology systems or those of third parties may fail or suffer security breaches, compromising sensitive information.
• Product liability lawsuits could lead to substantial liabilities, divert resources, and delay commercialization.
• Misconduct by employees, contractors, or partners, including noncompliance with regulatory standards or fraud.
• Unfavorable global and geopolitical economic conditions, including inflation and conflicts, could adversely affect business and financial results.
• Health epidemics may affect ability to initiate and complete studies, disrupt regulatory activities, manufacturing, and supply chain.
• Adverse effects from earthquakes, fires, natural disasters, or geopolitical events, with inadequate business continuity plans.
• Future product candidates may cause significant adverse events or side effects, delaying or preventing marketing approval.
• Failure to comply with obligations under government pricing programs (Medicaid, Medicare Part D, 340B, FSS) could result in penalties and fines.
• Expending limited resources on XDEMVY while failing to capitalize on potentially more profitable product candidates or indications.
• Ongoing regulatory obligations and review for XDEMVY and future products, potentially leading to restrictions or penalties.
• Improper promotion of off-label uses or misuse of products by ECPs could lead to sanctions and harm reputation.
• Changes in patent law could diminish the value of patents, impairing ability to protect products.
• Failure to identify relevant third-party patents or incorrect interpretation of their scope/expiration, affecting ability to develop and market products.
• Inability to obtain additional licenses for third-party technology or comply with existing license obligations.
• Inability to protect intellectual property rights throughout the world, especially in countries with weaker enforcement.
• Reliance on trade secrets and proprietary know-how, which are difficult to trace and enforce, and vulnerable to disclosure.
• Claims that employees or contractors have wrongfully used or disclosed confidential information of third parties.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Changes in healthcare law and regulations, including pricing and reimbursement policies, could adversely affect business.
• Increased regulatory scrutiny on direct-to-consumer marketing and telehealth pilot programs.
• Inadequate funding for the FDA and other government agencies could hinder timely product development and commercialization.
• Failure to comply with U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws.
• Failure to comply with health and data protection laws and regulations (e.g., GDPR, CCPA) could lead to penalties and reputational harm.

Future Outlook

The company expects to continue incurring significant operating expenses as it commercializes XDEMVY and advances its product candidates (TP-04 for ocular rosacea, TP-05 for Lyme disease prophylaxis) through clinical trials and potential commercialization. It anticipates funding operations through existing capital, XDEMVY sales, and potential future equity/debt financings or collaborations. Topline results for the ocular rosacea Phase 2 trial are expected in the first half of 2027. A Phase 2 clinical trial for TP-05 is planned for initiation in Q2 2026, with a potential partnership strategy for its Phase 3 development. Potential approval for a preservative-free TP-03 in Europe is expected in 2027, and in Greater China in 2026.

Management Comments

• XDEMVY is one of the best-selling prescription eye drops.
• XDEMVY has delivered remarkable results for patients and has generated more than $646 million in net product sales launch-to-date.
• Ocular rosacea is our next opportunity to create another potential blockbuster category in eye care.
• We believe that partnering the TP-05 program, following completion of the Phase 2 clinical trial, could be the best approach to potentially deliver this prophylactic therapy candidate to patients.
• We have assembled an exceptional management team with decades of deep strategic expertise building new markets across eye care and biotechnology.
• Our medical affairs and sales teams are sharing some of the positive MGD data with eye care professionals (ECPs), as these patients are already covered under XDEMVY's label for Demodex blepharitis.
• We believe TP-05 is currently the only on-demand, oral tablet in development that targets ticks and potentially prevents Lyme disease transmission.

Industry Context

StockSavvy.ai notes that Tarsus Pharmaceuticals is operating in a highly competitive biopharmaceutical industry characterized by rapid technological advancement and an emphasis on intellectual property. The company's focus on addressing root causes of diseases like Demodex blepharitis and ocular rosacea positions it in areas with high unmet medical needs and limited FDA-approved therapies. The success of XDEMVY in creating a new market for Demodex blepharitis treatment demonstrates a category-creating strategy, which, if replicated with TP-04 for ocular rosacea, could establish Tarsus as a leader in specialized eye care. The pursuit of TP-05 for Lyme disease prophylaxis also places it in a novel, non-vaccine space, potentially differentiating it from competitors like Valneva/Pfizer and Moderna in the vaccine market. The increasing scrutiny on drug pricing and data privacy regulations across the U.S. and EU reflects broader industry challenges that Tarsus must navigate.

Comparison to Industry Standards

• XDEMVY's gross margin of 93% in both 2025 and 2024 is exceptionally high, indicating strong pricing power and efficient manufacturing, which compares favorably to many established pharmaceutical products.
• The rapid increase in unaided awareness of Demodex blepharitis to 25% from 2% due to DTC campaigns suggests a highly effective market education strategy, potentially outperforming typical new product launches in niche therapeutic areas.
• The company's ability to secure over 90% commercial, Medicare, and Medicaid covered lives for XDEMVY demonstrates strong market access capabilities, which is a critical benchmark for new drug commercialization.
• While still incurring net losses, the significant reduction from $135.9 million in 2023 to $66.4 million in 2025, alongside substantial revenue growth, indicates a faster-than-average trajectory towards profitability for a commercial-stage biopharmaceutical company.
• The FDA's confirmation that a Phase 3 trial for TP-05 would require a disease prevention field study with thousands of patients is a standard, albeit challenging, requirement for prophylactic therapies, comparable to large-scale vaccine trials.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings. May become involved in ordinary course litigation, which could have an adverse impact due to costs, diversion of resources, and reputational harm.

Related Party Transactions

• In April 2024, the company purchased $3.0 million of preferred stock in an early clinical-stage private eye care company. In December 2025, an additional $0.9 million of preferred stock was purchased, totaling $3.9 million. Dr. Bobak Azamian (CEO and Chairman) and Dr. William Link (Director) serve on the board of this private company.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong XDEMVY sales growth and pipeline advancements, but also dilution from recent public offerings and ongoing net losses. Stock price volatility is a risk.
• Patients: Continued access to XDEMVY for Demodex blepharitis and potential new therapies for ocular rosacea and Lyme disease, addressing unmet medical needs.
• Eye Care Professionals (ECPs): Increased awareness and education regarding Demodex blepharitis and XDEMVY, with potential for new treatment options for MGD and ocular rosacea.
• Employees: Continued growth in employee numbers and investment in development, training, diversity, equity, and inclusion initiatives. Risk of competition for qualified personnel.
• Third-party Payers: Continued engagement to ensure broad access and affordability for XDEMVY, with ongoing challenges related to pricing regulations and reimbursement policies.
• Suppliers/Manufacturers: Continued reliance on third-party CMOs and single-source suppliers, creating interdependence and potential supply chain risks.

Next Steps

• Initiate a Phase 2 trial for TP-05 (Lyme disease prophylaxis) in the second quarter of 2026.
• Expect topline results from the Phase 2 trial for ocular rosacea in the first half of 2027.
• Seek potential approval of a preservative-free formulation of TP-03 for Demodex blepharitis in Europe, expected in 2027.
• Continue ongoing discussions with regulatory authorities in Japan for potential approval of TP-03 for Demodex blepharitis.
• GrandPharma, the partner in Greater China, expects potential approval of TP-03 for Demodex blepharitis in 2026.
• Potentially partner the TP-05 program after completion of the Phase 2 clinical trial for Lyme disease prophylaxis.
• Relocate corporate headquarters to a new facility in Irvine, California during 2026.

Key Dates

Recommendation

The company demonstrates strong commercial execution with XDEMVY, evidenced by significant revenue growth and increasing market penetration. The pipeline, particularly TP-04 and TP-05, shows promising clinical results and clear regulatory pathways, indicating future growth potential. While still incurring losses, the narrowing deficit and robust cash position from recent capital raises provide a solid foundation. The strategic focus on unmet medical needs and effective market education further supports a positive long-term outlook, making it an attractive investment for growth-oriented portfolios.

Keywords

Biopharmaceutical, Ophthalmology, Demodex Blepharitis, XDEMVY, Lotilaner, Ocular Rosacea, Lyme Disease Prophylaxis, Clinical Trials, FDA Approval, Drug Development, Commercialization, Eye Care, Infectious Disease, Pharmaceutical Sales, Intellectual Property, Biotech, Healthcare Regulation, SEC Filing